Target intelligence / Profile preview

Yes-associated protein 1 (YAP1) (YAP1)

Target
YAP1
Molecular classification
Transcription factor, Other
01

Overview

Yes-associated protein 1 (YAP1) is a key transcriptional coactivator and the primary downstream effector of the evolutionary conserved Hippo signaling pathway. When the Hippo pathway is active, upstream kinases (such as MST1/2 and LATS1/2) phosphorylate YAP1, leading to its cytoplasmic sequestration and proteasomal degradation. Conversely, when the Hippo pathway is inactivated or dysregulated (often due to mutations in tumor suppressors like NF2 or FAT1), unphosphorylated YAP1 translocates to the nucleus. Because YAP1 lacks a DNA-binding domain, it binds to TEA domain (TEAD) family transcription factors to drive the expression of genes involved in cell proliferation, survival, and migration, such as CTGF and CYR61.

Aberrant activation of YAP1 signaling is a major driver of tumorigenesis, metastasis, and drug resistance in various malignancies, including malignant pleural mesothelioma, colorectal cancer, non-small cell lung cancer, and head and neck squamous cell carcinoma. Consequently, the YAP1-TEAD transcriptional complex has emerged as a highly attractive therapeutic target. Drug development strategies include TEAD palmitoylation inhibitors (such as VT3989 and ODM-212) that destabilize the TEAD-YAP1 interaction, direct protein-protein interaction disruptors (such as IAG933), and antisense oligonucleotides (such as ION537) that target YAP1 mRNA for degradation. Notable clinical safety concerns associated with targeting this pathway include reversible albuminuria/proteinuria, QTc prolongation, and potential impairment of normal tissue regeneration and wound healing.

Other names
Yes-associated protein 1Transcriptional coactivator YAP1YAPYAP65Protein yorkie homologYes-associated protein YAP65 homolog
02

Mechanism of action

TEAD palmitoylation inhibition, YAP/TAZ-TEAD protein-protein interaction disruption, antisense oligonucleotide-mediated mRNA degradation

03

Biological functions

Signal transductionCell cycleApoptosisCell proliferationCell deathOther
04

Disease associations

CancerOther
05

Safety considerations

ProteinuriaAlbuminuriaQTc prolongationImpaired tissue regenerationImpaired wound healingIncreased lipaseNausea
06

Interacting drugs

7 more in the full profile.

07

Biomarkers

NF2 mutationFAT1 mutationYAP1 nuclear localizationCTGF expressionCYR61 expressionYAP1 amplification

Beyond the preview

Go deeper on Yes-associated protein 1 (YAP1) (YAP1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yes-associated protein 1 (YAP1) (YAP1).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call